PT - JOURNAL ARTICLE AU - Tai, Shi AU - Tang, Jianjun AU - Yu, Bilian AU - Tang, Liang AU - Wang, Yang AU - Zhang, Huilin AU - Zhu, Weihong AU - Xiao, Kui AU - Wen, Chuan AU - Tan, Chongqin AU - Jiang, Zhongbiao AU - Jiang, Chuanhao AU - Zhu, Li AU - Jiang, Li AU - Liu, Qiming AU - Hu, Xinqun AU - Fang, Zhenfei AU - Li, Xuping AU - Sun, Jiaxing AU - Zhu, Zhaowei AU - Yang, Hui AU - Tu, Tao AU - Xiao, Yichao AU - Chen, Mingxian AU - He, Yuhu AU - Chai, Xiangping AU - Xu, Junmei AU - Zhou, Shenghua TI - Association between Cardiovascular Burden and Requirement of Intensive Care among Patients with Mild COVID-19 AID - 10.1101/2020.05.25.20111757 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.25.20111757 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20111757.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.25.20111757.full AB - Background Information regarding the impact of cardiovascular disease (CVD) on disease progression among patients with mild coronavirus disease 2019 (COVID-19) is limited.Methods This study evaluated the association of underlying CVD with disease progression in patients with mild COVID-19. The primary outcome was the need to be transferred to intensive care due to disease progression. The patients were divided with and without CVD as well as stable and intensive care groups.Results Of 332 patients with mild COVID-19, median age was 51 years (IQR, 40-59 years), and 200 (61.2%) were female. Of 48 (14.5%) patients with CVD, 23 (47.9%) progressed to severe disease status and required intensive care. Compared with patients without CVD, patients with CVD were older, and more likely to have fatigue, chest tightness, and myalgia. The rate of requiring intensive care was significantly higher among patients with CVD than in patients without CVD (47.92% vs. 12.4%; P<0.001). In subgroup analysis, rate of requiring intensive care was also higher among patients with either hypertension or coronary heart disease than in patients without hypertension or coronary heart disease. The multivariable regression model showed CVD served as an independent risk factor for intensive care (Odd ratio [OR], 2.652 [95% CI, 1.019-6.899]) after adjustment for various cofounders.Conclusions Patients with mild COVID-19 complicating CVD in are susceptible to develop severe disease status and requirement for intensive care.Question What is the impact of coexisting cardiovascular diseases (CVD) on disease progression in patients with mild COVID-19?Findings Although most patients with mild COVID-19 were discharged alive from hospital, approximately 47.9% patients with coexisting CVD developed severe disease status and required intensive care. CVD is an independent risk factor of intensive care among patients with mild COVID-19.Meaning Coexisting CVD is associated with unfavorable outcomes among patients with mild COVID-19. Special monitoring is required for these patients to improve their outcome.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by grants from the Natural Science Foundation of China (81670269 and 81801394).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the National Health Commission of China and the institutional review board at Renmin Hospital of Wuhan University (Wuhan, China).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are included within the supplementary information file.